Search
Paclitaxel Treatment Options
A collection of 2030 research studies where Paclitaxel is the interventional treatment. These studies are located in the United States. Paclitaxel is used for conditions such as Breast Cancer, Ovarian Cancer and Non-Small Cell Lung Cancer.
1141 - 1152 of 2030
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Completed
This randomized phase II trial studies how well giving cabozantinib-s-malate or paclitaxel works in treating patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cavity cancer. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/28/2020
Locations: University of South Alabama Mitchell Cancer Institute, Mobile, Alabama +172 locations
Conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Completed
RATIONALE: Drugs used in chemotherapy, such as Abraxane, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth. Giving Abraxane together with lapatinib may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving Abraxane together with lapatinib works in treating patients with stage I, stage II, or stage II... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2020
Locations: Northwestern University, Northwestern Medical Faculty Foundation, Chicago, Illinois +4 locations
Conditions: Breast Cancer
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Completed
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving erlotinib together with carboplatin and paclitaxel may kill more tumor cells.
PURPOSE: This randomized phase II trial is studying how well erlotinib works when given alone or together with carbop... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
02/19/2020
Locations: Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas +123 locations
Conditions: Lung Cancer
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Completed
This phase II trial studies the effectiveness of paclitaxel in treating patients who have ovarian stromal cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
Gender:
FEMALE
Ages:
All
Trial Updated:
02/18/2020
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +97 locations
Conditions: Adult Type Ovarian Granulosa Cell Tumor, Ovarian Gynandroblastoma, Ovarian Sertoli-Leydig Cell Tumor, Ovarian Sex Cord Tumor With Annular Tubules, Ovarian Steroid Cell Tumor
A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies
Completed
The purposes of this study are to evaluate the safety and tolerability of sapanisertib (MLN0128) milled active pharmaceutical ingredient (API) capsules administered both as a single agent and in combination with paclitaxel, to characterize the effect of a high-fat meal on the pharmacokinetics (PK) of sapanisertib milled API capsules, and to characterize the PK of sapanisertib milled API capsules when administered on an empty stomach approximately 24 hours after paclitaxel infusion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2020
Locations: Not set, Scottsdale, Arizona +4 locations
Conditions: Non-hematologic Malignancy
PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation
Completed
To obtain preliminary data in a randomized phase II study whether PPX/RT improves progression-free survival as compared to temozolomide/RT for patients with GBM without MGMT methylation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2020
Locations: UCSD Cancer Center, La Jolla, California +8 locations
Conditions: Glioblastoma Multiforme
Neoadjuvant Paclitaxel Poliglumex, Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial (CTI#X64001)
Completed
Neoadjuvant Paclitaxel Poliglumex (PPX; CT-2103), Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial. (CTI#X64001
Gender:
ALL
Ages:
19 years and above
Trial Updated:
02/13/2020
Locations: Lifespan Hospitals, Providence, Rhode Island
Conditions: Esophageal Cancer
Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer
Completed
Cetuximab, Paclitaxel, Carboplatin and Radiation for Esophageal, Gastroesophageal Junction and Gastric Cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2020
Locations: Brown University Oncology Group, Providence, Rhode Island
Conditions: Esophageal Cancer, Gastric Cancer
BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study
Completed
The purpose of this study is to test the safety, activity and best doses of FOLFOX-A which consists of the standard chemotherapy drugs fluorouracil, leucovorin, oxaliplatin and abraxane. Each of these drugs are currently used in pancreatic cancer.
The experimental part of the study is combining these drugs together in FOLFOX-A.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2020
Locations: Memorial Hospital, Pawtucket, Rhode Island +2 locations
Conditions: Metastatic Pancreatic Cancer
A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies
Completed
The primary purpose of this study is to determine the safety profile and the maximum tolerated doses (MTDs)/ potential recommended phase 2 doses (RP2Ds) of the combination treatments of MLN2480 + MLN0128, MLN2480 + alisertib, MLN2480 + paclitaxel, MLN2480 + cetuximab, and MLN2480 + irinotecan in participants with advanced nonhematologic malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2020
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +13 locations
Conditions: Advanced Nonhematologic Malignancies
MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma
Withdrawn
This research study is being conducted to determine the effects of PEGPH20 plus chemotherapy treatment on the MRI characteristics of locally advanced pancreatic cancer patient tumors. Subjects will received Gemcitabine, Abraxane and PEGPH20.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2020
Locations: Abramson Cancer Center at University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Pancreatic Ductal Adenocarcinoma
Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors
Completed
The purpose of this study is to identify a safe and tolerable dose of BMS-906024 in combination with each of the following three chemotherapy regimens: Paclitaxel, 5FU plus Irinotecan (FOLFIRI), or Carboplatin plus Paclitaxel in subjects with advanced or metastatic solid tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2020
Locations: Usc/Norris Comprehensive Cancer Center, Los Angeles, California +4 locations
Conditions: Cancer
1141 - 1152 of 2030